Pemigatinib is a targeted therapy drug for specific cholangiocarcinoma patients. Its price is affected by factors such as dosage, region, and medical insurance policies. Specific prices should be obtained from hospitals or authorized pharmacies. This is a prescription drug; a professional physician must assess the patient's condition and prescribe it before use. Patients cannot purchase or adjust the dosage themselves.
I. Main Factors Affecting Price
Drug Dosage: Different dosages or packaging specifications (e.g., 4.5mg/tablet × 14 tablets) will affect the total price.
Regional Differences: Procurement policies and transportation costs at different medical institutions may cause price fluctuations.
Medical Insurance Policies: Pemigatinib is included in the medical insurance programs of some provinces and cities (e.g., the 2023 National Medical Insurance Catalog). After reimbursement, the out-of-pocket payment ratio may be reduced by 30%-70%. For specific details, please consult your local medical insurance department.
II. Channels for Cost Reduction
Medical Insurance Reimbursement: Patients meeting the indication (advanced cholangiocarcinoma with FGFR2 fusion/rearrangement) can apply for medical insurance reimbursement.
Charitable Drug Donations: Some pharmaceutical companies or foundations offer assistance programs; eligible individuals may receive partial cost reductions. Clinical Trials: Pay attention to clinical trials conducted by authoritative hospitals. Eligible patients may have the opportunity to receive free medication.
III. Precautions for Medication
Strictly Follow Doctor's Prescription: Regularly monitor blood phosphorus levels, liver function, and other indicators. Avoid stopping medication or changing the dosage on your own.
Side Effect Management: Common side effects include hyperphosphatemia, hair loss, and fatigue. Communicate with your doctor promptly regarding treatment options.
Medical Guidance: It is recommended to consult an oncology or hepatobiliary specialist at a tertiary hospital and confirm eligibility for medication through pathological testing (such as FGFR2 gene testing).
For specific pricing or purchasing procedures, it is recommended to consult through hospital pharmacies, reputable online hospitals, etc., and be wary of the risks associated with medications from unofficial channels.
